February 14, 2014
1 min read

Scottish Medicines Consortium accepts Iluvien for chronic DME

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Scottish Medicines Consortium, after assessing and reviewing a simple patient access scheme, has accepted Iluvien for restricted use within the National Health Service Scotland, according to a press release from Alimera Sciences.

Patients in Scotland considered insufficiently responsive to available therapies for chronic diabetic macular edema will now have access to Iluvien (sustained-release fluocinolone acetonide), according to the release. 

The advice is restricted to those with a pseudophakic eye, and re-treatment with Iluvien is predicated on a positive response to and subsequent need for the product, the release said.